Article

A new test can predict risk of colon cancer recurrence

Author(s):

The first test to determine risk of recurrence in stage 2 colon cancer could be available as soon as next year--good news for the roughly 30,000 patients diagnosed each year.The Oncotype DX colon cancer test (if that name sounds familiar, there's a similar test currently available for breast cancer) analyzes multiple genes to come up with a recurrence score for an individual tumor, researchers reported on Saturday at the annual meeting of the American Society of Clinical Oncology. Your doctor can then use that information to decide if you need chemotherapy after surgery.But even though the test successfully measured risk of recurrence, a separate set of genes meant to determine which patients would actually benefit from chemotherapy didn't work. But it's a work in progress. Investigators are now looking at a different set of genes that may work better to predict response to chemotherapy, said researcher David Kerr, MD, of the University of Oxford, at a press briefing prior to the meeting. We'll keep you updated on how that works out.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Imiage of two doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Related Content